SCHEMBL10344487

SCHEMBL10344487

O=S(O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.48
MAPT P10636 2/20 0.44
TRPV1 Q8NER1 3/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 2/20 0.39
AURKA O14965 1/20 0.39
TPX2 Q9ULW0 1/20 0.39
KIF11 P52732 1/20 0.39
NISCH Q9Y2I1 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
FAAH O00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1584405 0.98 EPHX2 (0.47) EPHX2MAPTTRPV1KMT2AGAA
SCHEMBL1584402 0.78 EPHX2 (0.43) EPHX2MAPTTRPV1KMT2AGAA
SCHEMBL10344177 0.77 CYP11B1 (0.43) MAPTGAANPC1RAB9A
SCHEMBL254957 0.76 MAPT (0.56) EPHX2MAPTTRPV1KMT2AGAA
SCHEMBL1584430 0.76 CYP11B1 (0.42) MAPTGAANPC1RAB9A
SCHEMBL2236991 0.75 KMT2A (0.43) MAPTKMT2ARAB9A
SCHEMBL9153089 0.74 CA1 (0.36)
Water SCHEMBL5129143 0.72 MMP2 (0.40) EPHX2KMT2AKIF11
SCHEMBL6368286 0.71 CA1 (0.52) NPC1RAB9A
SCHEMBL19190727 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230020161-A1 Tricyclic Modulators of PP2A RAPPTA THERAPEUTICS OY (FI) 2023-01-19 US disclosed
WO-2016183173-A1 ANTIPARASITIC COMPOUNDS Avista Pharma Solutions (US) 2016-11-17 WO disclosed
US-9067949-B2 Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia ALBANY MOLECULAR RESEARCH, INC. (US) 2015-06-30 US disclosed
US-8575186-B2 Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2013-11-05 US disclosed
US-20120184531-A1 BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-19 US disclosed
US-20110112122-A1 EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112122-A1 EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF HTR6, HTR3B, HTR1B EPHX2 220/4885MAPT 2717/4885TRPV1 577/4885
US-20230020161-A1 Tricyclic Modulators of PP2A PPP2CA, PPP4C, PPP3R1 EPHX2 4419/4885MAPT 1069/4885TRPV1 3769/4885
US-20120184531-A1 BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA HTR6, HTR5A, HTR2C EPHX2 1630/4885MAPT 1041/4885TRPV1 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.